Phosphorylation of Tyr sites of USP1 protein in K562 cell as a progression factor of chronic myeloid leukemia

  • S. V. Antonenko Institute of Molecular Biology and Genetics of Natl. Acad. Sci. of Ukraine, Ukraine, 03143, Kyiv, Akad. Zabolotnogo str., 150
  • Y. L. Polishchuk Institute of Molecular Biology and Genetics of Natl. Acad. Sci. of Ukraine, Ukraine, 03143, Kyiv, Akad. Zabolotnogo str., 150
  • G. D. Telegeev Institute of Molecular Biology and Genetics of Natl. Acad. Sci. of Ukraine, Ukraine, 03143, Kyiv, Akad. Zabolotnogo str., 150


Aim. To study the properties of Tyr phosphorylation of USP1 protein in K562 cells. Methods. The bioinformatics analysis of the USP1 protein sites of phosphorylayion using the Phosphosite software. Coimmunoprecipitation, Western blot. Immunofluorescence analysis and confocal microscopy. Results. Potential phosphorylation sites for USP1 protein for Tyr are provided. Phosphorylated form of USP1 protein detected in K562 cells. Using immunofluorescence analysis and confocal microscopy, we found that Tyr phosphorylated forms of USP1 protein are localized in the nucleus. Conclusions. We deem that Tyr phosphorylation of USP1 protein is the consequence of its interaction with Bcr-Abl oncoprotein, which has high kinase activity. USP1 phosphorylation can raise deubiquitinating activity of this protein, and as a result, avert the proteosomal degradation of Bcr-Abl in cell and facilitate the progress of the disease.
Keywords: chronic myeloid leukemia, Bcr-Abl, USP1, Tyr site of phosphorylation.


Antonenko S. V., Gurianov D. S, Тelegeev G. D. Colocalization of USP1 and РН domain of BcrAbl oncoprotein in terms of cronic myeloid leukemia cell rearrangements. Cytology and genetics. 2016. V. 50(4). P: 11–5. doi: 10.3103/S0095452716050 029.

Deininger M. W., Goldman J. M., Melo J. V. The molecular biology of chronic myeloid leukemia. Blood. 2000. V. 96. P: 3343–3356.

Fraile J. M., Quesada V., Rodriguez D., Freije J. M., Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012. V. 31. Р. 2373–2388. doi: 10.1038/onc.2011.443.

Iraia García-Santisteban, Godefridus J. Peters, Elisa Giovannetti, Jose Antonio Rodríguez USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Molecular Cancer. 2013. V. 12. P. 9. doi: 10.1186/1476-4598-12-91.

Jalkanen S., Lahesmaa-Korpinen A., Heckman C. Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Experimental hematology. 2012. V: 40 (9) P: 705–714. e3. doi: 10.1016/j.exphem.2012.05.010.

Kang Z. J., Liu Y. F., Xu L. Z., Long Z. J., Huang D., Yang Y., Liu B., Feng J. X., Pan Y. J., Yan J. S., Liu Q. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016 V.35:48. doi: 10.1186/s40880-016-0108-0.

Miroshnychenko D., Dubrovska A., Maliuta S., Telegeev G., Aspenström P. Novel role of pleckstrin homology domain of the Bcr-Abl protein: Analysis of protein-protein and protein-lipid interactions. Exp Cell Res. 2010. V. 316(4). P. 530–542. doi: 10.1016/j.yexcr.2009.11.014.

Olazabal-Herrero A., García-Santisteban I., Rodrí- guez J. A. Structure-function analysis of USP1: insights into the role of Ser313 phosphorylation site and the effect of cancer-associated mutations on autocleavage. Mol. Cancer. 2015 V. 14. P. 33. doi: 10.1186/s12943-015-0311-7.

Sun H., Kapuria V., Peterson L. F., Fang D., Bornmann W. G., Bartholomeusz G., Talpaz M., Donato N. J. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. 2011 V.117(11). P: 3151–62. doi: 10.1182/blood-2010-03-276477.

Xiomaris M. Cotto-Rios, Mathew J. K. Jones, Tony T. Huang. Insights into phosphorylation-dependent mechanisms regulating USP1 protein stability during the cell cycle. Cell Cycle. 2011. V.10:23. P: 4009–4016. doi: 10.4161/cc.10.23.18501.

Zhongxia Yu, Hui Song, Mutian Jia, Jintao Zhang, Wenwen Wang, Qi Li, Lining Zhang, Wei Zhao USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses. JEM. 2017, doi: 10.1084/jem.20170180.